Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will determine if docetaxel will be administered before or after doxorubicin/cyclophosphamides in an adjuvant chemotherapy regimen to be evaluated in a subsequent phase III trial.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Treatments: Cyclophosphamide; Docetaxel; Doxorubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• Must have histologically or cytologically confirmed breast cancer

• No metastatic disease

• Prior lumpectomy or mastectomy

• No prior chemotherapy or hormone treatments for breast cancer

• Must have normal organ and marrow function.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

Exclusion Criteria:

• Peripheral neuropathy of grade II or higher.

• History or evidence upon physical exam of CNS (central nervous system Diseases)disease.

• History of unstable angina or myocardial infarction within the last six months.

• Pregnant or nursing women.

• Known allergies to polysorbate 80.

• HIV-positive patients.